Pluristem says FDA lifts hold on muscle pain drug study

by admin on September 16, 2013

(Reuters) – Pluristem Therapeutics Inc said the U.S. Food and Drug Administration lifted its clinical hold on a mid-stage trial of the company's experimental drug for muscle pain. The company's shares rose 9 percent to $3.52 in premarket trading. The Israel-based company said the FDA allowed it to go ahead with the study, saying that Pluristem had addressed all issues related to the hold. The …

View full post on pain – Yahoo! News Search Results

Previous post:

Next post: